U.S. Neurologists Cautiously Optimistic Following Accelerated Approval and Launch of Eisai/Biogen’s Leqembi for Early Alzheimer’s Disease, According to Spherix Global Insights

Concerns about ARIA and the associated monitoring requirements for Leqembi could present significant barriers to uptake. EXTON, Pa., April 5, 2023 /PRNewswire/ — With the accelerated approval on January 6, 2023 for early Alzheimer’s disease, Eisai/Biogen’s Leqembi (lecanemab-irmb) became…

Click here to view original post